Core Insights - Qiagen reported revenue of $532.58 million for Q3 2025, a year-over-year increase of 6.1%, with an EPS of $0.61 compared to $0.59 a year ago, exceeding the Zacks Consensus Estimate of $525.99 million by 1.25% [1] - The company delivered an EPS surprise of 5.17%, with the consensus EPS estimate being $0.58 [1] Financial Performance - Qiagen's stock has returned -2.7% over the past month, while the Zacks S&P 500 composite increased by 2.1% [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating potential performance in line with the broader market [3] Sales by Product Groups - Diagnostic solutions - QIAstat-Dx: $32 million vs. $34.77 million estimated, +14.3% year-over-year [4] - Diagnostic solutions - QuantiFERON: $136 million vs. $133.3 million estimated, +11.5% year-over-year [4] - Diagnostic solutions - Other: $41 million vs. $39.24 million estimated, 0% year-over-year [4] - Other: $18 million vs. $17.37 million estimated, +28.6% year-over-year [4] - PCR / Nucleic acid amplification: $75 million vs. $76.5 million estimated, +1.4% year-over-year [4] - Genomics / NGS: $61 million vs. $60.62 million estimated, +10.9% year-over-year [4] - Diagnostic solutions total: $209 million vs. $207.61 million estimated, +6.1% year-over-year [4] - Sample technologies: $170 million vs. $163.77 million estimated, +4.9% year-over-year [4]

Core Viewpoint - Wall Street analysts predict that Qiagen (QGEN) will report quarterly earnings of $0.50 per share, reflecting a year-over-year increase of 6.4%, with revenues expected to reach $464.04 million, a 1.1% increase compared to the previous year [1]. Earnings Estimates - The consensus EPS estimate for the quarter has remained unchanged over the past 30 days, indicating that analysts have not revised their initial projections [2]. - Revisions to earnings estimates are crucial as they serve as indicators for predicting investor actions regarding the stock, with empirical research showing a strong correlation between earnings estimate trends and short-term stock price performance [3]. Revenue and Sales Forecasts - Analysts forecast 'Sales by Product Groups- Diagnostic solutions- QIAstat-Dx' to reach $30.15 million, indicating a year-over-year change of +20.6% [5]. - 'Sales by Product Groups- Diagnostic solutions- QuantiFERON' is expected to reach $111.16 million, reflecting a year-over-year increase of +10.1% [5]. - The average prediction for 'Sales by Product Groups- Sample technologies' is $150.54 million, suggesting a year-over-year decrease of -2.9% [6]. - 'Sales by Product Groups- Diagnostic solutions' is projected to be $180.35 million, indicating a year-over-year increase of +6.1% [6]. - 'Sales by Product Groups- Diagnostic solutions- NeuMoDx' is expected to reach $4.60 million, reflecting a significant year-over-year decrease of -48.9% [7]. - 'Sales by Product Groups- Genomics / NGS' is projected at $54.60 million, indicating a slight decrease of -0.7% from the prior year [7]. - 'Sales by Product Groups- PCR / Nucleic acid amplification' is expected to reach $67.64 million, reflecting a year-over-year decrease of -0.5% [8]. - 'Revenue- Molecular Diagnostics' is anticipated to be $252.58 million, indicating a year-over-year increase of +3.5% [8]. - The consensus estimate for 'Revenue- Life Sciences' stands at $211.17 million, reflecting a year-over-year decrease of -1.8% [9]. - 'Sales by Product Groups- Diagnostic solutions- Other' is expected to be $34.45 million, indicating a year-over-year decrease of -1.6% [9]. Stock Performance - Qiagen shares have shown a return of +6.2% over the past month, compared to the Zacks S&P 500 composite's +11.5% change, with a Zacks Rank 2 (Buy), suggesting that QGEN is expected to outperform the overall market in the near future [9].